15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies
March 02, 2021 09:00 ET | Sorrento Therapeutics, Inc.
Internally developed fully human anti-CD47 antibody (STI-6643) cleared for basket trial;No complicated titration or priming dose of the antibody is required to reduce toxicity;This study will be...